1-3 of 3
Yusri Elsayed
Close
Sort by
Journal Articles

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi W. Hilder, Jeffery Russell, Jeffrey Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg
Journal: Blood Advances
Blood Adv (2023) 7 (4): 644–648.
https://doi.org/10.1182/bloodadvances.2022007625
Published: 2023
Includes: Supplemental data
Journal Articles

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric Baldwin, Yingzhe Li, Xiaochun Zhang, Mark Mendonça, Nate Majewski, Rupesh Nanjunda, Diana Chin, Kathryn Packman, Yusri Elsayed, Ricardo Attar, François Gaudet
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4538–4549.
https://doi.org/10.1182/bloodadvances.2020002393
Published: 2020
Includes: Supplemental data
Journal Articles

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

Priyanka Nair-Gupta, Michael Diem, Dara Reeves, Weirong Wang, Robert Schulingkamp, Katrin Sproesser, Bethany Mattson, Bradley Heidrich, Mark Mendonça, Jocelin Joseph, Jocelyn Sendecki, Brad Foulk, Gerald Chu, Damien Fink, Qun Jiao, Sheng-Jiun Wu, Kathryn Packman, Yusri Elsayed, Ricardo Attar, François Gaudet
Journal: Blood Advances
Blood Adv (2020) 4 (5): 906–919.
https://doi.org/10.1182/bloodadvances.2019001188
Published: 2020
Includes: Supplemental data